Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C  by Da Silva, Diane M. et al.
Human papillomavirus-exposed Langerhans cells are activated by
stabilized Poly-I:C
Diane M. Da Silva a,b,1, Andrew W. Woodham c,1, Laurie K. Rijkee d, Joseph G. Skeate a,
Julia R. Taylor c, Maaike E. Koopman d, Heike E. Brand a, Michael K. Wong e,
Greg M. McKee f,2, Andres M. Salazar g, W. Martin Kast a,b,c,n
a Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
b Department of Obstetrics & Gynecology, University of Southern California, Los Angeles, CA, USA
c Department of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA, USA
d Groningen International Program of Science in Medicine, University of Groningen, Groningen, The Netherlands
e Department of Medicine, University of Southern California, Los Angeles, CA, USA
f Akela Pharma Inc., Austin, TX, USA
g Oncovir, Inc., Washington, DC, USA
a r t i c l e i n f o
Article history:
Received 27 March 2015
Received in revised form
11 May 2015
Accepted 11 May 2015
Available online 15 June 2015
Keywords:
Papillomavirus
HPV16
Langerhans cells
Immune escape
a b s t r a c t
Human papillomaviruses (HPV) establish persistent infections because of evolved immune evasion mechan-
isms, particularly HPV-mediated suppression of the immune functions of Langerhans cells (LC), the antigen
presenting cells of the epithelium. Polyinosinic-polycytidilic acid (Poly-I:C) is broadly immunostimulatory with
the ability to enhance APC expression of costimulatory molecules and inﬂammatory cytokines resulting in T
cell activation. Here we investigated the activation of primary human LC derived from peripheral blood
monocytes after exposure to HPV16 virus like particles followed by treatment with stabilized Poly-I:C
compounds (s-Poly-I:C), and their subsequent induction of HPV16-speciﬁc T cells. Our results indicate that
HPV16 particles alone were incapable of inducing LC activation as demonstrated by the lack of costimulatory
molecules, inﬂammatory cytokines, chemokine-directed migration, and HPV16-speciﬁc CD8þ T cells in vitro.
Conversely, s-Poly-I:C caused signiﬁcant upregulation of costimulatory molecules and induction of chemokine-
directed migration of LC that were pre-exposed to HPV16. In HLA-A*0201-positive donors, s-Poly-I:C treatment
was able to induce CD8þ T cell immune responses against HPV16-derived peptides. Thus, s-Poly-I:C
compounds are attractive for translation into therapeutics in which they could potentially mediate clearance
of persistent HPV infection.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
High-risk human papillomavirus (hrHPV) infection leads to the
development of several human cancers including cervical, vaginal,
vulvar, anal, and head and neck cancers that cause signiﬁcant
morbidity and mortality worldwide [1]. In particular, high risk
types HPV16 and HPV18 account for almost 70% of cervical cancer
development and the risk of cervical lesion progression is dis-
proportionately high for HPV16 [2,3]. More than 15% of women
that have hrHPV infections cannot initiate an effective immune
response against HPV, and among those that do, viral clearance is
very slow [4,5]. This suggests that HPV is escaping immune
detection and warrants the investigation of therapeutic treatments
that stimulate the immune system to clear HPV infections,
especially in women with consecutive positive hrHPV DNA tests.
We have previously implicated HPV-mediated suppression of
Langerhans cell (LC) immune function as a key mechanism in which
HPV evades immune surveillance [6–8]. LC are the local antigen
presenting cell (APC) of the epithelial and mucosal layers, making
them responsible for initiating immune responses against epithelium
invading viruses [9]. Upon proper pathogenic stimulation, LC undergo
phenotypic and functional changes including the activation of
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signaling cascades, the up-regulation of co-stimulatory molecules,
and the release of pro-inﬂammatory cytokines. Activated LC then
travel to lymph nodes via chemokine-directed migration where they
interact with antigen speciﬁc T cells and initiate an adaptive T cell
response (reviewed in [10]). However, LC exposed to HPV16 do not
become functionally mature APC, exhibit dysregulated cellular sig-
naling suggestive of HPV-induced suppression of LC function, and are
therefore unable to initiate HPV16-speciﬁc cytotoxic T cell responses
[6,7]. Elegant studies of LC depletion in murine epidermis have
challenged the notion that LC are required for initiating immune
responses to epicutaneous antigens, instead favoring a model in
which dermal dendritic cells (DC) are immunostimulatory and LC are
naturally immunoregulatory under homeostatic conditions [11–15].
Despite these intriguing ﬁndings, most human LC studies do not
demonstrate similar immunosuppressive effects. In contrast, human
LC, freshly isolated ex vivo or generated by in vitro differentiation,
have a very high capacity for cross-presentation of antigen and
inducing both CD8þ and CD4þ T cell responses [16–18].
Toll-like receptors (TLRs) are expressed by APC and recognize
pathogen associated molecular patterns (PAMPs). We have pre-
viously demonstrated that treatment with a TLR8 agonist can
activate LC, whereas a TLR7 agonist does not [19], suggesting that
the speciﬁc TLR molecule engaged on LC has a profound effect on
the resulting immune response. TLR3 is responsible for the
detection of viral dsRNA, and TLR3 signaling pathways initiate
antiviral and inﬂammatory responses [20]. TLR3 is found primarily
in the endosomes of APC including LC as well as on the surface of
epithelial cells [21,22]. Both natural and synthetic dsRNAs provide
warning signals through TLR3, inducing the production of type I
IFNs and other cytokines. The synthetic dsRNA viral analog
polyinosinic-polycytidylic acid (Poly-I:C) has long been known as
the strongest type I IFN inducer recognized by TLR3 [23], and
furthermore, can induce LC maturation via TLR3 stimulation [24].
Poly-I:C is a broad inducer of innate immunity and has been
investigated clinically for its adjuvant and anti-viral activity [25].
Despite its long-known potential, Poly-I:C is rapidly inactivated by
enzymes in blood, and is therefore not ideal for clinical applica-
tions [26]. However, Poly-I:C can be stabilized with polypeptides
(s-Poly-I:C) thereby promoting its use in the clinic [27]; Poly-I:C
stabilized with poly-arginine is known as Poly-ICR whereas Poly-I:
C stabilized with poly-lysine and carboxymethylcellulose is known
as Poly-ICLC. The primary objective of this study was to investigate
whether s-Poly-I:C can overcome HPV-induced immune suppres-
sion by functionally activating LC exposed to HPV16, and inducing
activation of HPV16-speciﬁc T cells in vitro.
2. Materials and methods
2.1. Healthy donor material
Ten healthy donors (male and female) between the ages of
24–40 years (average 2975.7 years) were recruited from the USC
Health Sciences Campus, and were enrolled into the study after a
brief physical and completing a short medical history question-
naire. Eligibility criteria included ability to give informed consent,
immune competence for leukapheresis collection, nonpregnant
status, and no history of clinical HPV disease. Written informed
consent for blood sampling was obtained from all individuals
under an approved Institutional Review Board protocol. Low
resolution HLA-A2 determination was performed for all partici-
pants using standard endpoint PCR and conﬁrmed by ﬂow
cytometry using an anti-HLA-A2 antibody on isolated leukocytes.
For HLA-A2 positive donors, high resolution HLA-A2 genotyping
was performed using the A*02 SSP UniTray Kit (Life Technologies,
Carlsbad, CA) to provide allele level typing at the HLA-A2 locus.
Blood samples were obtained by leukapheresis to enrich PBMC.
Leukocytes were puriﬁed immediately after collection using Lym-
phocyte Separation Media (Corning, Manassas, VA) by density
gradient centrifugation, and cryopreserved in liquid nitrogen.
2.2. Antibodies, reagents and HPV16 viral particles
HLA-ABC FITC, HLA-DP,DQ,DR-FITC, CD40 PE, CD80 FITC, CD86
FITC, CD83 PE, CD1a PE, puriﬁed anti-human CCR7, CD14 PE,
Langerin PE, TLR3 PE were purchased from BD Biosciences (San
Jose, CA). CD40 PE, puriﬁed rat IgG2a, goat anti-rat IgG PE, mouse
IgG1 FITC, mouse IgG1 PE were purchased from Biolegend (San
Diego, CA). Recombinant human (rhu)-CCL21 was purchased from
R&D Systems (Minneapolis, MN). Rhu-GM-CSF was manufactured
by Berlex (Seattle, WA) while rhu-TGFβ1 and rhu-IL-4 were
purchased from Biosource (Carlsbad, CA). Poly-ICR was provided
by Nventa Biopharmaceuticals/Akela Pharma (Austin, TX). Poly-
ICLC was provided by Oncovir, Inc. (Washington, DC) HPV16L1L2
virus-like particles (VLP) and chimeric HPV16L1L2-E7 VLP (HPV16
cVLP) were produced in insect cells and puriﬁed as previously
described [28]. Endotoxin levels in VLP preparations were found to
be below 0.06 EU using an E-toxate kit (Sigma-Aldrich).
2.3. Langerhans cell generation and characterization
LC were generated from human PBMC as previously described
[19]. Brieﬂy, PBMC and incubated in complete RPMI media with
the addition of 1000 U/mL GM-CSF, 1000 U/mL IL-4, and 10 ng/ml
TGFβ for 7 days. LC phenotype was conﬁrmed by ﬂow cytometry as
CD1aþLangerinþCD14 . Intracellular TLR3 expression was
assessed by ﬁxation and permeabilization (BD Cytoﬁx/Cytoperm
solution kit, BD Biosciences) of LC prior to intracellular staining
with a TLR3 antibody, following by ﬂow cytometry.
2.4. LC activation assay and ﬂow cytometry
LC were treated with HPV16 VLP prior to stimulation with TLR
agonists, and surface markers were detected by ﬂow cytometry as
previously described [29]. Brieﬂy, 106 LC were seeded in a 6-well
plate and either left untreated, treated with 10 μg HPV16 VLP, or
10 μg HPV16 VLP for 4 h prior to treatment with s-Poly-I:C, or with
s-Poly-I:C alone. After 48 h, the cells were harvested, washed,
stained for surface MHC I, MHC II, CD80, CD83, CD86, CD40, CCR7
or isotype controls, and analyzed on an FC500 ﬂow cytometer
using CXP software (Beckman Coulter). LC were gated on size
(large cells) based on forward and side scatter. Geometric mean
ﬂuorescence intensities (MFI) were used for data analysis based on
logarithmically acquired data.
2.5. In vitro migration of LC
Chemokine directed migration towards CCL21 of LC was carried
out using transwell plates (Costar, Cambridge, MA) as previously
described [30]. Brieﬂy, 2105 LC, untreated or treated with HPV16
VLP, s-Poly-I:C alone, or the combination of HPV16 VLP plus
s-Poly-I:C, as indicated above, were added to the upper chamber
in triplicate wells and incubated for 4 h at 37 1C. After 4 h, cells
that migrated to the lower chamber containing CCL21 or media
alone were counted using a Z1 Beckman Coulter particle counter.
Where indicated, a migration index was calculated as the number
of cells migrating to CCL21 over spontaneous migration for each
treatment group.
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2.6. Cytokine and chemokine analysis
Supernatants from 72 h cultures were assayed in triplicate
using the Bio-Plex Suspension Array System (Bio-Rad, Hercules,
CA) [29]. Cytokines and chemokines analyzed included IFNα, IL-1β,
IL-6, IL-12p70, IP-10, TNFα, MCP-1, MIP-1α, MIP-1β, and RANTES
using a custom MilliPlex MAP Human Cytokine/Chemokine Panel
per manufacturer's instructions (Millipore, Billerica, MA).
2.7. Mixed lymphocyte reaction (MLR) assay
The MLR assay was performed as previously described [6,31,32].
HLA-A*0201 LC were left untreated or treated with HPV16 VLP and
s-Poly-I:C and co-cultured with untreated, allogeneic, HLA-
mismatched CD4þ and CD8þ T cells puriﬁed from different donor
PBMC by negative magnetic separation (Miltenyi, San Diego, CA).
Responder (R) T cells and irradiated stimulator (S) LC were cultured
at R:S ratio of 20:1 in a 96-well round bottom plate in replicates of six
per treatment for 5 days. T cells and LC, each cultured alone, and T
cells cultured with autologous PBMC were used as negative controls,
while T cells cultured with phytohaemagglutinin (PHA, Sigma-
Aldrich) serve as a positive control. 3H-thymidine was added after
5 days to measure T cell proliferation. After an additional 18 h,
radioactive 3H-thymidine-pulsed cells were harvested and radio-
activity counted on a TopCount microplate liquid scintillation counter
(Perkin Elmer, Waltham, MA). Proliferation indices were calculated as
(mean radioactive cpm experimental/mean cpm of T cells alone).
2.8. In vitro immunization with HPV16 E7
Autologous CD8þ T cells and LC from HLA-A*0201þ donors were
co-cultured in vitro over several weeks to elicit primary CD8þ T cell
responses against HPV16 E7 using a previously described protocol
[6,30]. LC were generated as described above, and untouched CD8þ T
cells were puriﬁed from PBMC using a negative selection naïve CD8 T
cell isolation kit (Miltenyi Biotec, San Diego, CA). LC were left
untreated or exposed to HPV16-L1/L2-E7 cVLP, then left untreated
or treated with s-Poly-I:C. As a positive control, other LC treated with
s-Poly-I:C were exogenously loaded with HLA-A*0201 binding pep-
tides (E711–20, E782–90 and E786–93). CD8þ T cells and LC were co-
cultured with irradiated LC at a 20:1 (R:S) ratio for 7 days at 37 1C.
Cultures were restimulated with untreated or treated LC at days 7, 14
and 21. After 28 days T cells were harvested and tested for peptide-
speciﬁc IFN-γ production by ELISPOT.
2.9. IFN-γ ELISPOT assay
The ELISPOT assay was performed according to an established
laboratory protocol. 96-well multiscreen-HTS plates (Millipore)
were coated with 10μg/mL anti-human IFNγ (clone 1-D1K, Mab-
tech, Mariemont, OH) in PBS overnight at 4 1C, washed with PBS,
and blocked for 2 h with complete media at 37 1C. T cells collected
after in vitro immunization assays were plated at 2105 cells/well
in six replicate wells in the presence or absence of the HLA-A*0201
restricted peptides for 18 h at 37 1C, 5% CO2 [30]. Wells were
washed with PBS/0.5% Tween-20 and incubated with 1 mg/mL
biotinylated anti-human IFNγ antibody (clone 7-B6-1, Mabtech),
for 2 h followed by incubation for 1 h with streptavidin–HRP
(Sigma, St. Louis, MO). Spot development was carried out with
3-amino-9-ethyl-carbazole substrate (Sigma). Spots were counted
using the video-imaging KS ELISPOT analysis system (Carl Zeiss,
Thornwood, NY). The number of spots in the medium control wells
were subtracted from spots detected in antigen-speciﬁc stimula-
tion wells and was subsequently calculated as number of HPV
peptide-speciﬁc T cells per million PBMC.
2.10. Statistical analysis
Statistical analysis was performed using GraphPad Prism 6 (San
Diego, CA). Statistical signiﬁcance of the different assays (activa-
tion assay, cytokine and chemokine analysis, migration assay, MLR
assay, and in vitro immunization assay) was determined by a one-
way ANOVA for overall signiﬁcance followed by a Tukey's multiple
comparisons test comparing all columns for pooled experiments
from individual healthy donors. A non-parametric Kruskal–Wallis
statistical test following by Dunn's multiple comparisons test was
performed to verify the results of the statistical analysis for each
assay. Non-parametric Mann–Whitney U tests were performed for
representative experiments of technical replicates of single donors
performed in triplicate wells. Results with P-values o0.05 were
considered signiﬁcant.
3. Results
3.1. s-Poly-I:C (Poly-ICR) induces upregulation of MHC and
costimulatory molecules on HPV16-exposed LC
The phenotype of immature LC generated from PBMC was
deﬁned as high expression of CD1a, Langerin, MHC class I and class
II (Fig. 1a), similar to what has been shown for LC isolated from
skin ex vivo [21]. LC were positive for intracellular staining of TLR3,
negative for the monocytic marker CD14, and expressed low levels
of CD40, CD80, CD86 and the maturation marker CD83. These
immature LC were exposed to HPV16, followed by treatment with
s-Poly-I:C (Poly-ICR) and were then analyzed for the expression of
MHC and T cell co-stimulatory molecules. Exposure of LC to HPV16
VLP did not change expression of MHC and activation markers
compared to unexposed LC (Fig. 1b), similar to what has been
previously described [6]. In contrast, quantiﬁcation of activation-
associated markers from all donors indicated that treatment of LCs
with s-Poly-I:C after pre-exposure to HPV16 caused a signiﬁcant
upregulation of all surface markers analyzed (Fig. 1b), as measured
by higher levels of ﬂuorescent staining (mean ﬂuorescence inten-
sity) in all LC, not just a proportion of cells (data not shown).
Treatment of LC with s-Poly-I:C alone expectedly resulted in
upregulation of LC activation markers, in some cases (CD80,
CD83, CD86) resulting in a non-signiﬁcant but higher level of
stimulation than with the combination, consistent with the idea
that the presence of HPV16 VLP are somewhat suppressive to LC
activation (Fig. 1b). These results indicate s-Poly-I:C is able to
induce phenotypic activation of LC despite the presence of HPV16,
suggesting a potential reversal of the immune suppression caused
by HPV16 that we have previously demonstrated to be a dysregu-
lation of the PI3K/AKT pathway [7].
3.2. Poly-ICR induces HPV16-exposed LC to migrate to CCL21
LC chemokine-directed migration to regional lymph nodes
after receiving maturation signals in the periphery is required
for successful interaction with naïve T cells [33]. As an in vitro
correlate of LC migration in vivo, a transwell chemotaxis assay to
CCL21 was used to assess the migratory capacity of LC after
exposure to HPV16 followed by treatment with s-Poly-I:C (Poly-
ICR). CCL21 is a chemokine that is expressed in lymphoid organs
and signals through the maturation-induced CCR7 receptor on LC
during migration to lymph nodes [33]. Treatment of LC with either
s-Poly-I:C alone, or with s-Poly-I:C post HPV16 exposure resulted
in an increased trend in CCR7 expression (Fig. 2a) and a signiﬁcant
increase in migration capacity towards CCL21 compared to
untreated LC or LC exposed to HPV16 alone (Fig. 2b). Although
CCR7 expression was highly variable between individual donors,
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all six individual donors tested for LC migration responded with
similar robustness, indicating that even low levels of induced CCR7
expression are sufﬁcient to trigger chemokine-directed migration.
3.3. Poly-ICR induces HPV16-exposed LC to produce high levels of
inﬂammatory cytokines and chemokines
Induction of T cell responses against virus-infected cells
requires APC to produce Th1 inducing cytokines and chemokines
to prime CD8þ T cells against viral antigens and recruit innate
immune cells to participate in eradication of virus-infected cells.
Poly-I:C is well known for inducing a type I interferon response
through activation of transcription factors that leads to the
production of additional inﬂammatory cytokines and chemokines
[20,23]. Therefore, LC were tested for the ability to secrete a wide
variety of cytokines and chemokines after exposure to HPV16
followed by treatment with s-Poly-I:C (Poly-ICR). Only treatment
of s-Poly-I:C alone or HPV16-exposed LC plus s-Poly-I:C resulted in
a signiﬁcant increase in the magnitude of cytokines and chemo-
kines produced, most notably TNFα IFNα, IL-1β, IL-6, IL-12p70, IFN-
γ-inducible protein 10 (IP-10), MCP-1, MIP-1α, MIP-1β, and RANTES
(Fig. 3). These results demonstrate that HPV16-exposed LC are able
to secrete inﬂammatory cytokines and chemokines that can
activate and attract T cells to the site of antigen priming after
treatment with s-Poly-I:C.
3.4. HPV16-exposed LC treated with Poly-ICR induce HPV16-speciﬁc
CD8þ T cell responses
Activated LC are potent stimulators of T cell proliferation [34].
To determine whether s-Poly-I:C (Poly-ICR) treated HPV16-
exposed LC demonstrate an increased ability to stimulate naïve T
Fig. 1. Poly-ICR induces upregulation of MHC and costimulatory molecules on LC. (A) Immature LC were stained for CD1a, langerin, intracellular TLR3, CD14, MHC I, MHC II,
CD40, CD80, CD83, and CD86 and assessed via ﬂow cytometry; isotype control in gray. (B) Immature LC were left untreated or exposed to HPV16 VLP. Subsequently, cells
were treated with s-Poly-I:C (5 μg/mL Poly-ICR) for 48 h. Controls were left untreated, exposed to HPV16 VLP alone, or treated with s-Poly-I:C alone. Average fold increase in
LC surface marker expression. Data represent mean fold increase in surface marker expression (7SEM) relative to untreated LC based on mean ﬂuorescence intensity (MFI)
(N¼10 healthy donors). nnpo0.01, nnnpo0.001 compared to untreated LC and LC exposed to HPV16 (one-way ANOVA, Tukey's post-test).
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cell proliferation, an in vitro MLR assay was performed. Untreated,
HPV16-exposed, or HPV16-exposed and then s-Poly-I:C treated LC
were co-cultured with allogeneic T cells. LC treated with s-Poly-I:C
after HPV16 exposure or s-Poly-I:C alone demonstrated a signiﬁcant
enhancement of T cell stimulatory capacity compared to both
untreated LC alone and LC exposed to HPV16 VLP (Fig. 4a). To
analyze the ability of LC to induce antigen-speciﬁc T cells, we next
tested whether LC pre-incubated with HPV16 and then treated with
Poly-ICR induced an HPV16-speciﬁc CD8þ T cell response in ﬁve of
the HLA-A2þ donors after an in vitro immunization assay followed
by an IFNγ ELISPOT assay. In these experiments, HPV16 L1L2-E7
cVLP containing the E7 protein were used [28]. cVLP contain a
fusion protein of L2-E7, which encapsidates the E7 protein inside
the VLP and is delivered to LC as a viral antigen. Deﬁned HLA-
A*0201 binding E7 peptides [35] were used to detect the breadth
and magnitude of HPV16 E7-speciﬁc CD8þ T cell reactivity induced.
LC exposed to HPV16 cVLP and subsequently treated with s-Poly-I:C
were able to induce IFNγ secreting E7 peptide-speciﬁc CD8þ T cells
speciﬁc for all three epitopes, E711–20, E782–90, and E786–93, when
compared to untreated LC or LC exposed to HPV16 cVLP alone
(Fig. 4b). T cell responses tested against pooled E7 peptides were
found to be additive of individual peptide responses, indicating that
diverse T cells recognized each peptide individually (data not
shown). Collectively, these results demonstrate that LC exposed to
HPV16 particles and subsequently to s-Poly-I:C were able to become
functionally active and capable of inducing T cell proliferation and
an HPV16-speciﬁc CD8þ T cell response.
3.5. Poly-ICR and Poly-ICLC induce similar activated phenotypes in
HPV16-exposed LC
The above results show that s-Poly-I:C stabilized with poly-
arginine (Poly-ICR) induces phenotypically and functionally activated
LC that were pre-exposed to HPV16. Poly-I:C stabilized with poly-
lysine (poly-ICLC, Hiltonol), is an investigational dsRNA compound
that has been used in several past and present clinical trials as a
vaccine adjuvant [36–38]. Since Poly-ICLC can be more rapidly
translated to clinical studies in HPVþ women, we wanted to
determine its activity on HPV16-exposed LC and we hypothesized
that LC treatment with Poly-ICLC would similarly activate LC com-
pared to Poly-ICR. To examine this, LC were either left untreated or
exposed to HPV16 prior to treatment with Poly-ICR or Poly-ICLC and
then analyzed for cell-surface expression of costimulatory molecules.
The results demonstrate that LC treated with either Poly-ICR or Poly-
ICLC after HPV16 exposure had signiﬁcantly increased expression of
the costimulatory molecules CD40, CD80, CD83, and CD86 compared
to untreated and HPV16 only groups (Fig. 5). Notably, the level of
expression induced by Poly-ICR and Poly-ICLC was similar for all
markers tested when using the optimal concentration of each s-Poly-
I:C compound as determined by a dose titration (5 μg/mL Poly-ICR
and 50 μg/mL Poly-ICLC; Fig. S1). These results demonstrate that both
s-Poly-I:C compounds induce a similar activated phenotype in
HPV16-exposed LC.
3.6. Poly-ICLC induces LC activation in HPV16-exposed LC
Since Poly-ICR and Poly-ICLC induced similar increases in the
expression of costimulatory molecules, we next sought to deter-
mine if Poly-ICLC could induce functionally activated LC in a
comparable manner to what was observed for Poly-ICR. Therefore,
LC were treated with Poly-ICLC after pre-exposure to HPV16, and
LC activation was evaluated as the upregulation of MHC and
costimulatory molecules, in vitro chemokine-directed migration,
and secretion of inﬂammatory cytokines and chemokines.
Poly-ICLC was able to activate LC that had been pre-exposed to
HPV16 such that expression of the MHC I, MHC II, CD40, CD80,
CD83, and CD86 were signiﬁcantly increased (Fig. 6a). Treatment
of HPV16-exposed LC with Poly-ICLC resulted in a signiﬁcant
increase in migration capacity towards CCL21 compared to
untreated LC or LC exposed to HPV16 alone (Fig. 6b). Similar to
Poly-ICR, treatment of HPV16-exposed LC with Poly-ICLC resulted
in a signiﬁcant increase in the amount of cytokines and chemo-
kines secreted (Table S1). Similar to what we observed for Poly-ICR
(Figs. 1–3), LC treatment with Poly-ICLC alone caused similar levels
of phenotypic and functional activation to that observed with LC
treatment of Poly-ICLC after exposure to HPV16 (data not shown).
Taken together these results indicate that Poly-ICLC can induce the
functional activation of HPV16-exposed LC, providing a strong
rationale for testing Poly-ICLC in future clinical applications.
4. Discussion
The life cycle of hrHPV is strictly intraepithelial, and consequently
viral antigens should be processed and presented by LC, the profes-
sional APC that reside in the epithelium [39]. Various studies have
found that HPV16 VLP can bind to and stimulate the activation of
human dendritic cells (DC) [32,40], providing evidence that HPV16
can induce the maturation of APC subsets. Immature LC express low
levels of phenotypic activation markers and cytokines in the absence
Fig. 2. Poly-ICR induces HPV16-exposed LC to upregulate CCR7 and migrate to
CCL21 in vitro. LC were exposed to HPV16 prior to s-Poly-I:C (Poly-ICR) treatment as
described. (A) CCR7 expression was analyzed by ﬂow cytometry. Data represent
mean fold increase in CCR7 expression (7SEM) relative to untreated LC based on
MFI (N¼10 individual donors). (B) In vitro migration assay. LC were analyzed for
migration through a transwell insert to CCL21 or medium alone. Shown is the mean
number of LC migrating to CCL21 (black bars) compared to spontaneous migration
(7 SEM) relative to untreated LC (N¼6 individual donors). nnpo0.01 compared to
untreated LC and LC exposed to HPV16 (one-way ANOVA, Tukey's post-test).
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of activating stimuli. Therefore, exposure to HPV16 would not be
expected to cause a reduction of those levels. However, based on our
previous data, we know that the interaction of HPV16 and other
hrHPV types with LC results in a suppressive signaling cascade
through interference with the PI3-K/Akt signaling pathway, sugges-
tive of active immune suppression [7,8]. Moreover, we have deter-
mined defective LC activation to be dependent on the presence of the
HPV16 L2 minor capsid protein binding to a cell surface receptor that
causes a decrease in phenotypic activation and stimulatory capacity
of LC [41,42]. In this regard, LC may be uniquely manipulated by HPV
compared to other immune cells or DC subsets. Because other HPV
genotypes such as high-risk (HPV18, HPV31, and HPV45), low-risk
(HPV11), and a cutaneous (HPV5) genotype, also suppress LC activa-
tion through a similar mechanism [8], an immune modulating
treatment such as s-Poly-I:C shown for HPV16 is likely to have
efﬁcacy against other hrHPV types as well.
The ﬁeld of LC biology is still evolving as new technologies allow
unprecedented investigation into the functions of discreet populations
Fig. 3. Poly-ICR induces HPV16-exposed LC to produce high levels of inﬂammatory cytokines and chemokines. LC were exposed to HPV16 prior to treatment with s-Poly-I:C
(Poly-ICR) (N¼7 individual donors). Cell supernatants were analyzed for a panel of ten cytokines and chemokines using a Bio-Plex Suspension Array System. Data represent
the mean (7SEM) analyte concentration. npo0.05, nnpo0.01, nnnpo0.001, nnnnpo0.0001 compared to untreated LC and LC exposed to HPV16 (one-way ANOVA, Tukey's
post-test).
Fig. 4. HPV16-exposed LC treated with Poly-ICR induce T cell proliferation and an HPV16-speciﬁc CD8þ T cell response. (A) Mixed lymphocyte reaction. Proliferation of
allogeneic T cells by HPV16-exposed LC treated with Poly-ICR. LC were left untreated or exposed to HPV16 VLP for 6 h (N¼4 individual donors). Subsequently, the cells were
treated with s-Poly-I:C (5 μg/mL Poly-ICR) for 48 h. LC were co-cultured with puriﬁed MHC-mismatched T cells from a healthy donor for 6 days in triplicate wells. 3H-
thymidine was added during the last 18 h of culture. Shown is the mean cpm thymidine uptake (7 SEM) npo0.05 compared to untreated LC (one-way ANOVA, Tukey's post-
test). (B) In vitro immunization. Puriﬁed CD8þ T cells were co-cultured with s-Poly-I:C (5 μg/mL Poly-ICR) treated or untreated autologous LC for 4 weeks with weekly
restimulations in an in vitro immunization assay. LC were loaded with HPV16 L1L2-E7 cVLP, then treated with s-Poly-I:C or left untreated. T cells were then tested for IFN-γ
secretion in response to HLA-A*0201 binding peptides by ELISPOT analysis. The number of spots representing IFNγ secreting cells was averaged over eight replicate wells.
Data show two representative HLA-A*0201þ donors following s-Poly-I:C treatment of LC out of ﬁve donors tested.
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of APC subsets [43]. Although mouse studies are pointing towards an
immunoregulatory role for LC under homeostatic conditions, it is not
presently clear whether the situation in genetically engineered mice is
representative of the in vivo function of human LC. One barrier
preventing correlation of human studies with mouse in vivo experi-
ments is the disparate expression of various surface receptors used for
phenotyping DC subsets and relative functional plasticity of APC
depending on the presence of different inﬂammatory stimuli. Indeed,
recent transcriptional proﬁling of puriﬁed mouse and human DC
subsets reveals that human LC are most functionally similar to the
mouse CD8αþCD103þ dermal DC subpopulation [44]. Moreover, both
of these populations are highly adept at cross-priming naïve CD8þ T
cells into effector CTLs. It is also very likely that the actual function of
LC in situ, whether mouse or human, is determined by stimuli from
the environment including danger signals, epithelial cell cross-talk,
and presence of other immune cells and soluble mediators [45].
Regardless of the current controversies as to the nature and functions
of LC, it is evident that HPV either speciﬁcally manipulates LC in a
suppressive manner, or takes advantage of the inherent immunor-
egulatory functions of LC, thereby avoiding immune detection and
viral clearance; however, our data demonstrate this situation can be
reversed by providing an immunostimulatory TLR3 signal with s-Poly-
I:C that allows maturation steps to proceed.
Here we demonstrate that TLR3 is expressed by monocyte-
derived LC. Likewise, it has been demonstrated that LC freshly
isolated from human skin also express TLR3 and are capable of
responding to dsRNA [21]. Highly-puriﬁed LC freshly isolated from
human epidermis are strongly activated by Poly-I:C as indicated by
marked increases in the expression of CD40, CD80, and CD86 [24].
Furthermore, Poly-I:C treatment commits LC to induce CD8þ T cell
responses more effectively than dermal DC [46]. Renn et al.
demonstrated that LC derived from CD34þ umbilical cord pro-
genitor cells responded better to Poly-I:C than do monocyte
derived DC [47]. While these previous in vitro reports indicate
that Poly-I:C may be promising in inducing human LC-mediated
immune responses, these studies do not consider the rapid
degradation of non-stabilized Poly-I:C by serum nucleases present
in humans and non-human primates [26], limiting their applic-
ability to clinical research, which is why only stabilized Poly-I:C
compounds were chosen for the current investigations.
The results of the current study show that LC are not activated
by and do not induce an adaptive immune response to HPV16
alone. Despite this, LC from all donors were able to become
functionally active APC, upregulating MHC and costimulatory
molecules, undergoing chemokine-directed migration, secreting
inﬂammatory cytokines and chemokines, and inducing CD8þ T
cell responses after treatment with s-Poly-I:C (either Poly-ICR or
Poly-ICLC) in vitro. However, our study has limitations in that the
LC are blood-derived rather than isolated from the cervical
mucosa. Despite this, the aforementioned LC studies of others
suggest that freshly isolated epidermal LC and LC derived from
monocytes or CD34þ progenitors respond similarly to Poly-I:C.
Fig. 5. Poly-ICLC induces upregulation of costimulatory molecules on LC similar to Poly-ICR. Immature LC were left untreated or exposed to HPV16 VLP prior to treatment
with s-Poly-I:C (Poly-ICR or Poly-ICLC). Control cells were left untreated or were exposed to HPV16. Expression of CD40, CD80, CD83, and CD86 and was then analyzed by
ﬂow cytometry. The average fold increase in LC surface marker expression from one representative donor out of four tested is presented. Data shown is the mean fold
increase in surface marker expression (7SD) of triplicate values relative to untreated LC based on MFI. np¼0.05 (Mann–Whitney U test).
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Fig. 6. Poly-ICLC induces LC activation in HPV16-exposed LC. (A) Poly-ICLC induces upregulation of MHC and costimulatory molecules on LC. LC were left untreated or
exposed to HPV16 prior to treatment with s-Poly-I:C (50 μg/mL Poly-ICLC), then analyzed by ﬂow cytometry for indicated surface markers. Control cells were left untreated
or exposed to HPV16 alone. Data shown is the mean fold increase in surface marker expression (7SD) of replicate values relative to untreated LC based on MFI of one
representative donor out of four tested. np¼0.05, (Mann–Whitney U test). (B) Poly-ICLC induces HPV16-exposed LC to migrate to chemokine CCL21 in vitro. LC were exposed
to HPV16 prior to s-Poly-I:C (50 μg/mL Poly-ICLC). LC were analyzed for migration to medium or medium supplemented with CCL21. Shown is the mean number (7SD) of LC
migrating to CCL21 (black bars) compared to spontaneous migration (white bars) of three separate donors performed in triplicate relative to untreated LC. *p¼0.05
compared to HPV16 only LC (Mann–Whitney U test).
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Additionally, our culture system does not replicate the complex
interactions that take place in vivo between epithelial cells, LC, and
lymphocytes along with cytokine cross-talk.
Two studies have demonstrated the utility of using Poly-I:C in
the adjuvant setting for HPV-related disease. Intravaginal treatment
with Poly-I:C after systemic vaccination has been shown to increase
mucosally associated E7-speciﬁc CD8þ T cell responses in mice [48].
Increased mucosal trafﬁcking of T cells in that model is likely the
result of chemokine upregulation, as it has been shown in this study
and by others that Poly-I:C is a strong inducer of chemokine
secretion. A dose-dependent increase in the secretion of the
chemokine IL-8/CXCL8 was observed when human endocervical,
ectocervical, and vaginal epithelial cells were treated with Poly-I:C
in vitro, indicating that cells at the cervical transformation zone,
which is highly susceptible to hrHPV infection, would be responsive
to TLR3 agonists [49]. Poly-ICLC has also been used to enhance the
systemic Th1 immune responses against a HPV16 capsomer vaccine
in rhesus macaques, supporting the induction of strong anti-HPV16
L1 antibody responses [50]. Taken together, these studies suggest
that TLR3 activation may act through multiple mechanisms of
action to stimulate both innate and adaptive immunity to promote
HPV clearance if applied in the right context. For example, one
could envision short-term topical application of Poly-ICLC in a
cervical cap or in a dissolvable patch that could be applied to the
cervix of women with recently detected hrHPV-positive test results
obtained during regular screening intervals in order to stimulate LC
activation while virus transcriptional activity is still present.
In the current study, we demonstrated that LC responded strongly to
two different poly-peptide stabilized forms of poly-I:C. Poly-ICR induced
robust responses in LC, and these results were then conﬁrmed with
clinical grade Poly-ICLC. Effective concentrations for LC activation by
unstabilized Poly-I:C in in vitro studies has been reported between 10–
25 mg/mL [24,46], which is similar to concentrations used for Poly-ICR
and Poly-ICLC in the current study. The effective dose of Poly-ICLC
needed to achieve equivalent activation marker upregulation, for
example, was ﬁve to ten times the effective dose of Poly-ICR (Fig. S1).
The differences in the optimal concentrations for Poly-ICR and Poly-ICLC
could be due to variations in manufacturing practices, the latter being a
cGMP-produced compound, or the use of poly-arginine versus poly-
lysine as a stabilization component. In vitro, the mechanism of action of
either Poly-I:C or stabilized Poly-I:C (Poly-ICLC) appears to result in
similar gene expression and transcriptional proﬁles after stimulation of
PBMC, suggesting that the improved in vivo activity of Poly-ICLC may be
related to the stabilization effect rather than differences in TLR3 ligation
[51]. While both stabilized compounds tested in this study demonstrate
the capability of initiating potent LC-mediated immune responses in the
presence of HPV16, Poly-ICLC, which is produced in clinical grade
batches by Oncovir under the name Hiltonol, is currently being used in
clinical trials including studies to stimulate immunity against solid
tumors and in dendritic cells vaccines [36–38].
Collectively our observations suggest that the TLR3 agonist
s-Poly-I:C is a promising therapeutic molecule that can stimulate
LC immune function without potential interference or suppression
of LC signaling by HPV, and result in LC capable of stimulating
anti-HPV CD8þ T cell-mediated immune responses. Looking for-
ward, due to its pharmaceutical grade availability, good safety
proﬁle in human clinical studies, and current results reported
herein, the use of Poly-ICLC to promote LC activation in vivo in
hrHPV positive women should be explored further clinically in
order to induce anti-HPV immunity and enhance viral clearance.
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